Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that new data from the ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s ...

In this GEN webinar, DNA synthesis experts Michael Junkin, PhD, and Brittany Enzmann, PhD, will provide an exclusive first look at Elegen’s GEN II Cell-Free DNA production platform that combines ...

A blood test that uses artificial intelligence (AI) to detect cancer-related genetic changes and protein biomarkers could help screen women for early signs of ovarian cancer, according to a new study.

HAYWARD, Calif.--(BUSINESS WIRE)--Aqtual, Inc., a precision medicine company with a novel active chromatin cell-free DNA (cfDNA ac) platform to develop products for chronic diseases and oncology, ...

Please provide your email address to receive an email when new articles are posted on . Biopsies with high donor-derived cell-free DNA levels were likely to reveal antibody-mediated rejection.

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...